Clinical trials: Chronic Nephropathy
Autosomal Dominant Polycystic Kidney Disease
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
This study will assess whether everolimus (RAD001) is effective in preventing cyst and kidney expansion as well as worsening of renal function in patients with ADPKD and whether the application of 5 mg/day everolimus as…
- Trial name
- NCT00414440
- Testing
- Everolimus
- Where
- 24 sites in Austria, France and 1 more
- Volunteers
- 431 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Diseases, Patient Requiring Heparin Free Dialysis Treatments
Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™
This study will assess the safety and efficacy of heparin free hemodialysis (HD) performed with dialyzers with Endexo in adult end-stage renal disease (ESRD) subjects on thrice-weekly in-center HD.
- Trial name
- NCT04511338
- Testing
- Dialyzer with Endexo
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fresenius Medical Care North America
Chronic Kidney Disease, Endothelial Dysfunction
Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation
The study is about possible protective effects of paricalcitol (Zemplar) upon inflammation, blood pressure and kidney function. Kidney Inflammation occurs when white blood cells become abnormally stimulated and accumulate in the…
- Conditions
- Chronic Kidney Disease, Endothelial Dysfunction, Inflammation, Hypertension
- Trial name
- NCT00428246
- Testing
- paricalcitol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Indiana University
Kidney Failure, Acute, Kidney Failure, Chronic
Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?
The kidneys are highly vascular organs and any trauma or surgery poses risk of severe bleeding. Platelet function is an integral part of the blood clotting during the initial, so-called vascular phase.
- Conditions
- Kidney Failure, Acute, Kidney Failure, Chronic, Blood Platelet Disorders, Hemorrhage
- Trial name
- NCT00334204
- Testing
- measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Mississippi Medical Center
Anaemia
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease
This study aims to characterize the relationship between dose of GSK1278863 and hemoglobin (Hgb) response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD).
- Trial name
- NCT02019719
- Testing
- GSK1278863
- Where
- 21 sites in Japan
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Anaemia
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in approximately 68 subjects with anemia…
- Trial name
- NCT01587898
- Testing
- GSK1278863
- Where
- 55 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C
Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
This study will examine the effectiveness of pegylated interferon, or peginterferon (a long-acting form of alpha interferon) plus ribavirin in treating hepatitis C (genotype 1) infection with and without kidney disease.
- Trial name
- NCT00028093
- Testing
- Peginterferon alfa-2a with Ribavirin, Peginterferon alfa-2a
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Calciphylaxis, Calcific Uremic Arteriolopathy
Phase 2 Study With SNF472 in Calciphylaxis Patients
To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).
- Trial name
- NCT02790073
- Testing
- SNF472
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Sanifit Therapeutics S. A.
Renal Transplantation
Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
Efficacy and safety of 2 groups of treatment: everolimus in association with cyclosporine microemulsion and steroids versus everolimus in association with Enteric-coated Mycophenolate Sodium (EC-MPS) and steroids.
- Trial name
- NCT00425308
- Testing
- Everolimus + Cyclosporine, Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS), Steroids
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
The purpose of the present study is to investigate the association between the accumulation of advanced glycation end-products (AGE) and adverse outcomes (e.g.
- Trial name
- AGED (NCT02878317)
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- University of Nottingham
End Stage Renal Disease
Dialysis Catheter Comparative Clinical Trial
The purpose of this clinical trial is to compare the longevity of two dialysis catheters.
- Trial name
- NCT00526123
- Testing
- Symmetric Tip Catheter, Conventional Split-tip Catheter
- Where
- 14 sites in United States
- Volunteers
- 599 people
- Sponsor
- Tyco Healthcare Group
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis
The primary objectives of this study were to determine the rate, extent, and routes of radioactivity excretion of [¹⁴C]etelcalcetide in feces, dialysate, and urine over time and to measure radioactivity concentrations in whole…
- Trial name
- NCT02054572
- Testing
- [¹⁴C]Etelcalcetide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Amgen
Chronic Kidney Disease, Bloodpressure
Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD
The transition from chronic kidney disease (CKD) to end-stage renal disease ESRD is a vulnerable and challenging period of time for patients and providers.
- Conditions
- Chronic Kidney Disease, Bloodpressure, Hypertension
- Trial name
- PERFORMANCE (NCT02975505)
- Testing
- Strict blood pressure control
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- University of California, San Francisco
Anemia, Chronic Kidney Disease (CKD)
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
The purpose of this study is to show biosimilarity of HX575 epoetin alfa with the US licensed reference product Epogen®/Procrit® when applied subcutaneously.
- Trial name
- ACCESS (NCT01693029)
- Testing
- HX575 epoetin alfa, US-licensed epoetin alfa
- Where
- 52 sites in United States
- Volunteers
- 435 people
- Sponsor
- Sandoz
Multiple Myeloma, Chronic Kidney Disease
Optimising Renal Outcome in Myeloma Renal Failure
The purpose of this study is to compare the effectiveness of bortezomib versus thalidomide in reducing free light chains in the blood of myeloma patients.
- Trial name
- OPTIMAL (NCT02424851)
- Testing
- Bortezomib, Thalidomide, Bendamustine
- Where
- 9 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Oxford University Hospitals NHS Trust
Cardiovascular Disease, Chronic Kidney Disease
Vascular Risk After Kidney Transplantation
Hypothesis: Nontraditional risk factors, such as inflammation, vitamin D deficiency, elevated PTH, insulin resistance, homocysteine, or uric acid, contribute to cardiovascular disease progression after kidney transplant.
- Conditions
- Cardiovascular Disease, Chronic Kidney Disease, Diabetes, Vitamin D Deficiency
- Trial name
- NCT00374595
- Where
- United States
- Volunteers
- 338 people
- Sponsor
- University of Nebraska
Anemia
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
This single arm study will assess the efficacy and safety of intravenous Mircera, administered with pre-filled syringes, for the treatment of anemia in patients with chronic kidney disease who are on dialysis, and who have…
- Trial name
- NCT00413894
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 105 sites in Germany
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis
This single-arm study will assess the efficacy and safety of monthly administration of SC Mircera for the maintenance of hemoglobin levels in participants with chronic kidney disease on peritoneal dialysis.
- Trial name
- MISTRAL (NCT00737477)
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 52 sites in France
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
End Stage Renal Disease, Renal Impairment
A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 120 mg dose in participants with end stage renal disease (ESRD) before and after hemodialysis (HD)…
- Trial name
- NCT04994522
- Testing
- Belzutifan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
End-Stage Renal Disease
Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease
The goal of this study is to evaluate the role of nutritional Vitamin D deficiency as a potential contributor to the morbidity witnessed in patients with end-stage renal disease
- Trial name
- NCT00677534
- Testing
- Cholecalciferol
- Volunteers
- 7 people
- Sponsor
- University of Kansas